A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Next Previous
Trial Profile

A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Acronyms FAB-C
  • Sponsors Zynerba Pharmaceuticals

    • Most Recent Events

    • 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, company will collect significant amount of important data from this study and will present or publish this data during this year.
    • 14 Nov 2017 According to a Zynerba Pharmaceuticals media release, 13 of the 18 patients completing the study have enrolled into the 52-week open label extension and remain in the trial
    • 28 Sep 2017 According to a Zynerba Pharmaceuticals media release, primary endpoint ( total score of Anxiety, Depression, and Mood Scale) met at week twelve.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top